Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria. Denman S, Smith H, Arumugakani G, Mistry A, et al. Clin Exp Dermatol 2022;47:2002-2005.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Denman S, Smith H, Arumugakani G, Mistry A, et al. Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria. Clin Exp Dermatol 2022;47:2002-2005.
PMID: 35775857